Dr. Cusnir on the Utilization of Y-90 Maintenance in CRC

Mike Cusnir, MD, chief, Division of Hematology and Oncology, co-director, Gastrointestinal Malignancies, Mount Sinai Medical Center, discusses the utilization of SIR-Spheres® Y-90 resin microspheres as maintenance therapy in colorectal cancer (CRC).

Liver-directed therapies will have multiple benefits for patients, Cusnir explains. Utilizing Y-90 resin in patients with advanced CRC to target the liver, the main sight of disease in most patients, may allow patients to receive intervals of systemic treatment, as well as prolong life, Cusnir says.

Y-90 resin should have an earlier role in the treatment of patients with CRC in the maintenance setting to achieve the optimal response, Cusnir continues. There may also be a spot for Y-90 resin in the chemorefractory setting, as there are many heavily pretreated patients that are seen for clinical trials that have never been treated with Y-90 resin, Cusnir adds. Ultimately, disease that is localized in the liver is where Y-90 resin will excel, Cusnir concludes.